Successful management of severe congestive cardiac failure with enalapril.
The new angiotensin-converting enzyme inhibitor enalapril (MK-421) was administered to a patient with severe congestive cardiac failure. Dramatic and sustained symptomatic and hemodynamic improvement is reported. The possible clinical significance of this agent's favorable profile is briefly discussed.
D004151:Dipeptides / Q000627:therapeutic use*; D004656:Enalapril; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006333:Heart Failure / Q000188:drug therapy*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged
D004151:Dipeptides; D004791:Enzyme Inhibitors; D004656:Enalapril